CompletedPhase 2NCT03484819
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
Studying Primary mediastinal large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Nabila N Bennani, M.DMayo Clinic Cancer Center LAO
- Intervention
- Copanlisib Hydrochloride(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2024
Study locations (15)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
- HaysMed, Hays, Kansas, United States
- University of Kansas Cancer Center, Kansas City, Kansas, United States
- The University of Kansas Cancer Center - Olathe, Olathe, Kansas, United States
- Ascension Via Christi - Pittsburg, Pittsburg, Kansas, United States
- Salina Regional Health Center, Salina, Kansas, United States
- University of Kansas Health System Saint Francis Campus, Topeka, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
- University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
- University Health Truman Medical Center, Kansas City, Missouri, United States
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States
- Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
- Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03484819 on ClinicalTrials.govOther trials for Primary mediastinal large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1NCT07168486CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell LymphomasUniversity of Maryland, Baltimore
- RECRUITINGPHASE2NCT06500273Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLAllogene Therapeutics
- ACTIVE NOT RECRUITINGPHASE1NCT05757700Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell LymphomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT05653271ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell MalignanciesAcepodia Biotech, Inc.
- ACTIVE NOT RECRUITINGNCT06024694Primary Mediastinal Large B-cell Lymphoma With CNS InvolvementIRCCS San Raffaele
- RECRUITINGNCT05366569Bio-CAR-T BS StudyAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- ACTIVE NOT RECRUITINGPHASE3NCT04759586Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT04745949PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyM.D. Anderson Cancer Center
See all trials for Primary mediastinal large B-cell lymphoma →